Lupin partners with AbbVie to treat haematological cancers

Lupin Limited has partnered with the global pharmaceutical company AbbVie Incorporated. AbbVie has licensed Lupin's MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.

Through this partnership, AbbVie has gained exclusive global rights to develop and commercialize Lupin’s MALT1 inhibitors, informed the company in a filing to the bourses. MALT1 is a protein involved in T-cell and B-cell lymphocyte activation and AbbVie intends to pursue development across a range of haematological cancers.

As per the terms of the agreement, AbbVie will pay Lupin an upfront payment of US$30 million for an exclusive license to the program. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to US$947 million. Additionally, Lupin will be entitled to receive a double-digit royalty on the sales of the product and will retain commercial rights to the program in India.

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. It intends to use its expertise across four therapeutic areas: immunology, oncology, virology and neuroscience.

On Friday, the stock of Lupin closed at Rs. 857.35 per share. On Monday, by opening at Rs. 861 its surged by 2.11 per cent to make intra-day high of Rs. 875.45.